Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
|
Laparoscopic versus Open Complete Mesocolic Excision and D3 Lymphadenectomy in Right Colon Carcinoma
Background and objectives: Complete mesocolic excision (CME) technique seems to be gaining popularity in cancer colon management. We aim to compare the laparoscopic approach for CME with the open approach in right colon cancer treatment regarding the feasibility, safety and perioperative and oncologic outcomes.
Patients and methods: A prospective study which included all patients that underwent radical right hemicolectomy for pathologic confirmed stage II or stage III tumor with CME at South Egypt Cancer Institute, Assiut University from January 2012 to December 2019.
Patients were grouped according to the surgical approach into the laparoscopic colectomy (LCME) group (n=48) or the open colectomy (OCME) group (n=48).
Results: The mean operative time was significantly longer in the LCME group than in the OCME group with less mean intraoperative blood loss. The conversion was required in 4 patients (8.3%) in the LCME group. The use of laparoscopy increased the number of harvested lymph nodes than in the open approach (39.81+-16.74 vs 32.65 +-12.28, respectively, P=0.010). The laparoscopic approach was associated with a shorter time interval to first flatus and shorter time interval to liquid and normal diet after surgery.
The postoperative hospital stay was significantly shorter in the LCME group (9.13+-1.57 day) than in the OCME group (13.04+-3.07 day). The complication rate was slightly lower in the LCME (14.7%) than in the OCME group (27.2 %), (P=0.252).
The 3-years OS in the LCME group was similar to that in OCME (78.2% vs 63.2%, respectively, P-value = 0.423). The three years DFS in the laparoscopic group was higher (74.5%) than the open group (60.0%) but didnâ??t reach statistical significance (P-value = 0.266).
Conclusions: In conclusion, laparoscopic CME right hemicolectomy is a technically feasible and safe procedure if surgeon expertise is present. LCME has long-term oncologic outcomes (recurrence and survival) comparable to open surgery for the management of patients with stage II or III colon cancer.
Full Text Sources:
Abstract:
Views: 1652
Patients and methods: A prospective study which included all patients that underwent radical right hemicolectomy for pathologic confirmed stage II or stage III tumor with CME at South Egypt Cancer Institute, Assiut University from January 2012 to December 2019.
Patients were grouped according to the surgical approach into the laparoscopic colectomy (LCME) group (n=48) or the open colectomy (OCME) group (n=48).
Results: The mean operative time was significantly longer in the LCME group than in the OCME group with less mean intraoperative blood loss. The conversion was required in 4 patients (8.3%) in the LCME group. The use of laparoscopy increased the number of harvested lymph nodes than in the open approach (39.81+-16.74 vs 32.65 +-12.28, respectively, P=0.010). The laparoscopic approach was associated with a shorter time interval to first flatus and shorter time interval to liquid and normal diet after surgery.
The postoperative hospital stay was significantly shorter in the LCME group (9.13+-1.57 day) than in the OCME group (13.04+-3.07 day). The complication rate was slightly lower in the LCME (14.7%) than in the OCME group (27.2 %), (P=0.252).
The 3-years OS in the LCME group was similar to that in OCME (78.2% vs 63.2%, respectively, P-value = 0.423). The three years DFS in the laparoscopic group was higher (74.5%) than the open group (60.0%) but didnâ??t reach statistical significance (P-value = 0.266).
Conclusions: In conclusion, laparoscopic CME right hemicolectomy is a technically feasible and safe procedure if surgeon expertise is present. LCME has long-term oncologic outcomes (recurrence and survival) comparable to open surgery for the management of patients with stage II or III colon cancer.
Full Text Sources:
Abstract:
Views: 1652
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Dec 2025
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.